Balancing Nature with Science to Produce
Safe & Effective Innovative Therapies
with Targeted Selective Properties
Se-cure is a research-driven pharmaceutical company founded in 1997, which has developed a proprietary platform for the discovery, development and scaling of therapies from botanical origin.
Implementing proprietary botanical therapies development and scaling technologies, Se-cure introduces novel biochemical agents characterized by functionally selective mechanisms of action in target tissues providing safe and effective solutions to medical needs.
Products For Instant Marketing
Endorsed by the Medical Societies as 1st Line Treatment
DTC
Strong International Brands
TECHNOLOGY
Our expertise lies in the development of proprietary botanical therapies using the unique properties in the plant origin to create innovative APIs that have the ability to selectively target specific tissues, without affecting unwanted tissues and thus, develop safe and effective therapies that can be used for the long-term without imposing risks on the users.
Close
Standardization is a major challenge in developing therapies from a botanical source. In the development of botanical APIs multiple variables come into play which require monitoring and control to secure standardization.
Se-cure applies an integrated methodology to guarantee product standardization and batch to batch therapeutic consistency.
In a cGMP production facility, Se-cure practices its multi-layer standardization control methodology:
Raw material standardization – a proprietary process developed in house, stabilizing the botanical raw material from yield to yield, providing API consistency with a clear fingerprint.
In-line controls – analytical tools monitor consistency of formulations while in process, and bio-chemical tools monitor the presence of residuals and microorganisms.
Finished product controls – analytical tools are used for the finished product release criteria.
Se-cure’s stringent botanical API and finished product’s specifications and controls, ensure the highest quality of its products.
Close
TECHNOLOGY
Our expertise lies in the development of proprietary botanical therapies using the unique properties in the plant origin to create innovative APIs that have the ability to selectively target specific tissues, without affecting unwanted tissues and thus, develop safe and effective therapies that can be used for the long-term without imposing risks on the users.
Close
Standardization is a major challenge in developing therapies from a botanical source. In the development of botanical APIs multiple variables come into play which require monitoring and control to secure standardization.
Se-cure applies an integrated methodology to guarantee product standardization and batch to batch therapeutic consistency.
In a cGMP production facility, Se-cure practices its multi-layer standardization control methodology:
Raw material standardization – a proprietary process developed in house, stabilizing the botanical raw material from yield to yield, providing API consistency with a clear fingerprint.
In-line controls – analytical tools monitor consistency of formulations while in process, and bio-chemical tools monitor the presence of residuals and microorganisms.
Finished product controls – analytical tools are used for the finished product release criteria.
Se-cure’s stringent botanical API and finished product’s specifications and controls, ensure the highest quality of its products.
Close
Proven international success
Accompanied by training sessions
Innovative & attractive marketing materials
Professional support and guidance along the way
Years of experience, deep knowledge and many success stories
Close
Join Us
Brizo®
Targets Men's Urinary Health. Urinary urgency and overactive bladder symptoms affect more than half the population of men in their 50's and this percentage grows to as many as 90% of men in their 70's.Being the most common form of ailment, an overactive bladder leads to bothersome urinary symptoms affecting men’s life both during the day and night, and considerably impacts men’s quality of life.
The most common cause of overactive bladder symptoms in men is the enlargement of the prostate as men age.
Brizo® is intended for all men who suffer from irritable lower urinary tract issues associated with the aging of the prostate gland.
The API in Brizo®, SC012 originates from the soybean plant undergoing a unique process, creating a substance that selectively targets the prostate gland itself targeting several pathways that are at the base of the enlargement of the prostate which leads to urinary symptoms without leading to any unwanted effects.
SC012 selectively activates and bonds to ERβ (agonistic activity) while restraining the stimulatory action of ERα (antagonist activity), this process controls prostatic growth. In addition, SC012 bonds and blocks Androgen Receptors (antagonistic effect), blocking the ability of Dihydrotestosterone (DHT) to attach to the AR and encourage prostate proliferation.
This combined mechanism provides a significant relief of the bothersome urinary symptoms within the 1st month of use, felt by the lessening of the urge to urinate during the day and night.
For more information you are invited to visit: www.brizo-bph.com
Close
Fermarelle®
Our first line of products targets Women Healthcare, providing women risk free, effective solutions for the management of their post-reproductive life.The decline in estrogen levels starting in women’s 40s, leads to a chronic hormonal imbalance affecting women from this stage onwards. This change dramatically impacts women’s quality of life, from the onset of ‘menopausal’ symptoms to the progression of post-menopausal diseases.
The Femarelle® line provides a targeted solution to the needs of the woman:
- Femarelle® Rejuvenate is indicated for the primary transition of estrogen decline- targeting women 40+.
- Femarelle® Recharge is indicated for the classical menopause transition- targeting women 50+.
- Femarelle® Unstoppable is indicated for the more mature women- targeting women 60+.
The API developed in-house- DT56a is at the core of each product in the line, targeting the estrogen receptors while each product contains different vitamins and minerals, boosting the beneficial impact on the target tissue.
DT56a, is a non-hormonal proprietary API, originating from the soybean plant, processing the 20 amino acids within the soybean, creating, a unique compound that has been modulated to form the desired effect within the woman’s body, by bonding to the estrogen receptors without being recognized by the body as estrogen, thus developing a non-hormonal botanical therapy that was declared in 2017 as the 1st line treatment for the management of menopause at the European Society of Gynecology.
DT56a, a standardized compound with a clear fingerprint, mimics the structures that are recognized by estrogen receptors in the woman’s body as estrogen, bound together with either a co-activator or co-repressor, depending on the tissue forming a SERM (Selective Estrogen Receptor Modulator), having either an agonistic (activation) or antagonistic (blocking) effect on the estrogen receptors, depending on the target tissue.
In the tissues where we want to motivate estrogen receptor activation, such as the brain and the bone, DT56a mimics the bond of estrogen with a specific co-activator, thus providing the benefits of estrogen. Whilst where an activation is not wanted, such as in the breast and uterus, DT56a attaches to the estrogen receptor by mimicking the bond of estrogen to a co-repressor, thus forming a blocking effect, so as not to cause any proliferation in the reproductive tissues, which is not needed any longer.
This process provides a targeted solution of estrogen receptor bonding, without being recognized by the body as estrogen, thus, providing the benefits of therapy without exposing the body to the risks.
For more information on the Femarelle line you are invited to visit: www.femarelle.com
Close
Being the most common form of ailment, an overactive bladder leads to bothersome urinary symptoms affecting men’s life both during the day and night, and considerably impacts men’s quality of life.
The most common cause of overactive bladder symptoms in men is the enlargement of the prostate as men age.
Brizo® is intended for all men who suffer from irritable lower urinary tract issues associated with the aging of the prostate gland.
The API in Brizo®, SC012 originates from the soybean plant undergoing a unique process, creating a substance that selectively targets the prostate gland itself targeting several pathways that are at the base of the enlargement of the prostate which leads to urinary symptoms without leading to any unwanted effects.
SC012 selectively activates and bonds to ERβ (agonistic activity) while restraining the stimulatory action of ERα (antagonist activity), this process controls prostatic growth. In addition, SC012 bonds and blocks Androgen Receptors (antagonistic effect), blocking the ability of Dihydrotestosterone (DHT) to attach to the AR and encourage prostate proliferation.
This combined mechanism provides a significant relief of the bothersome urinary symptoms within the 1st month of use, felt by the lessening of the urge to urinate during the day and night.
For more information you are invited to visit: www.brizo-bph.com
The decline in estrogen levels starting in women’s 40s, leads to a chronic hormonal imbalance affecting women from this stage onwards. This change dramatically impacts women’s quality of life, from the onset of ‘menopausal’ symptoms to the progression of post-menopausal diseases.
The Femarelle® line provides a targeted solution to the needs of the woman:
- Femarelle® Rejuvenate is indicated for the primary transition of estrogen decline- targeting women 40+.
- Femarelle® Recharge is indicated for the classical menopause transition- targeting women 50+.
- Femarelle® Unstoppable is indicated for the more mature women- targeting women 60+.
The API developed in-house- DT56a is at the core of each product in the line, targeting the estrogen receptors while each product contains different vitamins and minerals, boosting the beneficial impact on the target tissue.
DT56a, is a non-hormonal proprietary API, originating from the soybean plant, processing the 20 amino acids within the soybean, creating, a unique compound that has been modulated to form the desired effect within the woman’s body, by bonding to the estrogen receptors without being recognized by the body as estrogen, thus developing a non-hormonal botanical therapy that was declared in 2017 as the 1st line treatment for the management of menopause at the European Society of Gynecology.
DT56a, a standardized compound with a clear fingerprint, mimics the structures that are recognized by estrogen receptors in the woman’s body as estrogen, bound together with either a co-activator or co-repressor, depending on the tissue forming a SERM (Selective Estrogen Receptor Modulator), having either an agonistic (activation) or antagonistic (blocking) effect on the estrogen receptors, depending on the target tissue.
In the tissues where we want to motivate estrogen receptor activation, such as the brain and the bone, DT56a mimics the bond of estrogen with a specific co-activator, thus providing the benefits of estrogen. Whilst where an activation is not wanted, such as in the breast and uterus, DT56a attaches to the estrogen receptor by mimicking the bond of estrogen to a co-repressor, thus forming a blocking effect, so as not to cause any proliferation in the reproductive tissues, which is not needed any longer.
This process provides a targeted solution of estrogen receptor bonding, without being recognized by the body as estrogen, thus, providing the benefits of therapy without exposing the body to the risks.
For more information on the Femarelle line you are invited to visit: www.femarelle.com
Burn Management
Dental Bone Rejuvenation
Burn Management
Dental Bone Rejuvenation